EQ 300
EQ 300 Dragon Pharma — Overview
EQ 300 Dragon Pharma is an injectable boldenone undecylenate solution at 300 mg/mL — the single-compound, higher-concentration version of Dragon Pharma's boldenone line. Unlike the EQ 200 / Test E 200 blend, EQ 300 contains no testosterone component; it must always be stacked with a testosterone base. The product is designed for users who want full control over the individual doses of each compound in their cycle rather than the fixed ratio of a pre-mixed blend.
Boldenone undecylenate is a modified testosterone derivative with a long 11-carbon ester that produces a sustained-release profile. Its primary practical value over testosterone in a stack is a meaningfully lower aromatization rate — roughly half that of testosterone per milligram — combined with pronounced erythropoiesis stimulation, reliable appetite increase, and lean-quality tissue accrual. One key timing rule for this product: because the undecylenate ester has a half-life of approximately 14 days, PCT should begin 21 days after the last injection to allow plasma levels to clear sufficiently for SERM-driven HPTA recovery.
About the Compound: Boldenone Undecylenate
Boldenone is a synthetic anabolic-androgenic steroid derived from testosterone by the addition of a double bond between carbons 1 and 2. This modification reduces the compound's androgenic potency relative to testosterone and slows its rate of aromatization to estradiol. The undecylenate ester — an 11-carbon fatty acid chain attached at the C17 position — controls the release rate after intramuscular injection, producing a plasma half-life of approximately 14 days and a full active life extending beyond three weeks. Because of this slow-release profile, several weeks of consistent injection are required before plasma concentrations stabilize, which is the primary reason EQ cycles typically run 12–16 weeks rather than the 8–10 weeks common for shorter-ester compounds.
Boldenone exerts its effects primarily through direct androgen receptor agonism — the same mechanism as testosterone. Where it differs from testosterone in meaningful ways: its aromatization to estradiol occurs at approximately 50% the rate of testosterone per milligram, so estrogen-related sides are less pronounced at equivalent doses; it converts to dihydroboldenone (DHB) via 5-alpha reductase rather than dihydrotestosterone, which is relevant for users monitoring scalp and prostate sensitivity; and it stimulates erythropoiesis (red blood cell production) more reliably and to a greater degree than testosterone at equivalent doses — the erythropoietic effect is the compound's most clinically notable characteristic and its most important monitoring consideration.
What EQ 300 Does
- Lean, quality mass accrual — boldenone drives androgen receptor-mediated protein synthesis and nitrogen retention with a lower estrogenic burden than testosterone, producing tissue gains that are denser and drier in appearance; glycogen-driven water retention is minimal compared to testosterone-only or testosterone plus Dianabol cycles; gains are steady and tend to be well-retained post-cycle.
- Significant appetite stimulation — one of boldenone's most consistent and pronounced practical effects; the increase in hunger is meaningful enough to make the compound particularly valuable in bulking phases where caloric surplus is a limiting factor; users who struggle to eat enough during mass cycles often find EQ removes that barrier within the first two to three weeks of stable blood levels.
- Erythropoiesis and improved oxygen delivery — boldenone stimulates renal erythropoietin (EPO) production, which increases red blood cell count and hematocrit; at doses of 300–600 mg/week over a 12–16 week cycle, hematocrit elevation of 3–6 percentage points is common; this produces improved endurance, better muscle pump, and enhanced vascularity as body composition leans out — but requires monitoring to prevent hematocrit from reaching ranges associated with cardiovascular risk.
- Vascularity — the combination of increased red blood cell density and the leaner tissue quality that boldenone promotes makes subcutaneous veins more visible as body fat decreases; this is a secondary benefit of the erythropoietic effect rather than a fat-burning or direct cosmetic mechanism.
- Moderate androgenic activity — boldenone's androgenic potency is lower than testosterone's but not negligible; users experience the general well-being, libido support, and strength drive associated with androgenic compounds, though these effects are less pronounced than with equivalent milligram doses of testosterone — which is why a testosterone base remains mandatory for hormonal balance and libido maintenance throughout the cycle.
On timing: Because of the undecylenate ester's slow release, EQ 300 requires at least 4–6 weeks to reach stable plasma concentrations. Users who assess results at week 4 will underestimate the compound — the full appetite, vascularity, and mass effects become apparent from week 6 onward. Cycles shorter than 12 weeks do not give the compound enough time to express fully.
Who It Is For
EQ 300 is appropriate for intermediate to advanced users who have already run at least one testosterone-only cycle successfully and want to add a second compound that raises cycle quality without meaningfully increasing estrogenic burden. It is not a first-cycle compound — hematocrit monitoring, AI calibration for a lower-aromatizing environment, and a 12-week minimum commitment all require prior AAS experience to manage correctly. All Dragon Pharma products referenced below are available at Steroid Warehouse.
EQ 300 vs the EQ 200 / Test E 200 blend: the pre-mixed blend locks both compounds into a fixed 1:1 ratio; EQ 300 lets you run boldenone at any dose independently of testosterone — useful when the target weekly EQ dose does not match the target test dose, or when cycling testosterone propionate (shorter ester) instead of enanthate. If the 1:1 ratio at 400–800 mg total per week suits your protocol, the blend is the simpler choice; if it does not, EQ 300 is the right product.
EQ 300 vs Primobolan: both compounds deliver lean, dry tissue gains with low water retention and low aromatization. Primobolan does not aromatize at all and carries lower androgenic potency — the softer option for users sensitive to androgenic sides or who want minimal AI management. EQ 300 is the stronger choice when appetite stimulation is a priority, when erythropoiesis-driven endurance and vascularity matter, and when cost-per-milligram is a factor — boldenone is significantly more affordable than methenolone at equivalent doses.
When to choose something else: users who need faster, heavier mass gains with stronger anabolic output should look at Deca 300 alongside testosterone, or add a Dianabol kickstart. Users who cannot commit to 12+ weeks should not run boldenone — the long ester does not reach full expression in shorter cycles. Users whose baseline hematocrit already reads above 47% should address that before adding a compound that further elevates RBC mass.
EQ 300 at 300 mg/mL means one milliliter delivers the full low-end weekly dose in a single injection. Users working up to 600 mg/week split two milliliters across two equal pins per week to keep plasma levels stable given the long ester.
EQ 300 vs Alternatives
Boldenone undecylenate occupies a specific position in the injectable AAS lineup — lean-mass, low-estrogenic, high endurance and vascularity output. The table below compares EQ 300 to the compounds users most commonly consider alongside or instead of it.
| Compound | Key Differences vs EQ 300 | Choose EQ 300 When | Choose the Alternative When |
|---|---|---|---|
| Primobolan 100 DP | Zero aromatization; lower androgenic potency; no erythropoietic effect; significantly higher cost per mg | Appetite stimulation is needed; endurance, RBC elevation, and vascularity are goals; cost-per-mg matters | Androgenic sensitivity is high; zero AI management is preferred; budget allows premium pricing for methenolone |
| Deca 300 DP | Stronger anabolic output; more water retention and volumizing effect; joint cushioning; requires cabergoline standby for prolactin/progesterone activity | Lean, dry tissue gains are the priority; avoiding prolactin management; vascularity and endurance are cycle goals | Mass and strength are the primary targets; joint discomfort is an active concern; managing prolactin risk is acceptable |
| Masteron 200 DP | DHT-derived; anti-estrogenic; no aromatization; no appetite or erythropoietic effect; primarily a hardening and cosmetic compound | Building phase; body fat above 15%; appetite stimulation and RBC effects are valued | Body fat is below 12%; cutting or contest-prep phase; already running high testosterone where Masteron's anti-estrogenic activity is directly useful |
| EQ 200 / Test E 200 DP | Pre-mixed 1:1 boldenone-to-testosterone enanthate blend; simpler protocol but no independent dose control of each compound | Independent dosing of boldenone and testosterone is needed; running a non-enanthate testosterone ester (e.g. propionate) | Target weekly boldenone and testosterone doses are equal; simplicity and fewer distinct vials matter |
Recommended Combinations
All combinations below use Dragon Pharma products available at Steroid Warehouse. Boldenone requires a testosterone base in every cycle; EQ 300 alone without testosterone causes HPG axis suppression without adequate androgenic hormonal support.
| Goal | Compounds | Notes |
|---|---|---|
| Foundation / Lean Bulk | EQ 300 DP 300–400 mg/week + Enantat 250 DP 400–500 mg/week |
Standard entry stack for the compound; Test E provides the hormonal base and androgen drive; EQ adds appetite, RBC elevation, and leaner tissue quality; 12–16 weeks; inject both E3.5D |
| Mass / Strength | EQ 300 DP 400–600 mg/week + Enantat 400 DP 400–800 mg/week |
Higher-output bulk stack; Enantat 400 reduces injection volume for the testosterone component; increased total dose raises erythropoietic and appetite effects from boldenone — monitor hematocrit every 4–6 weeks; AI required at this dose range |
| Recomp / Pre-Contest | EQ 300 DP 300–400 mg/week + Propionat 100 DP 300–400 mg/week + Masteron 200 DP 400 mg/week |
Dry stack for body composition improvement; Masteron lowers SHBG, contributes androgenic hardness, and adds mild anti-estrogenic activity; Propionat 100 allows tighter control of testosterone level with shorter ester; best suited to users below ~15% body fat to appreciate the visual benefits; 10–14 weeks |
| Advanced Volume | EQ 300 DP 400 mg/week + Enantat 250 DP 400–500 mg/week + Deca 300 DP 300 mg/week |
Triple long-ester stack; Deca adds joint lubrication and volumizing mass; EQ provides appetite and vascularity alongside Deca's anabolic output; do not run this stack without experience managing both nandrolone-related prolactin risk and boldenone hematocrit; prolactin management (cabergoline) on standby; 14–16 weeks; PCT wait is governed by the longest ester (21 days for both boldenone and nandrolone) |
Side Effects & Management
| Side Effect | Mechanism | How to Handle It |
|---|---|---|
| Hematocrit / RBC elevation | Boldenone stimulates renal EPO production, increasing red blood cell mass; at 300–600 mg/week over 12–16 weeks, hematocrit commonly rises to 48–54%; values above 52% carry meaningful cardiovascular risk from increased blood viscosity and clotting tendency | Run Aspirin 75 mg/day (Ecosprin) starting week 1 as a baseline antiplatelet measure; check CBC at weeks 4, 8, and end of cycle; if hematocrit exceeds 52%, reduce dose or consider therapeutic phlebotomy; this is the primary safety monitoring point for any EQ cycle |
| HDL suppression / lipid imbalance | AAS class effect — boldenone suppresses HDL cholesterol and can elevate LDL; the effect is less pronounced than with 17-alpha-alkylated orals but relevant at doses above 400 mg/week over extended cycle lengths | Lipid panel at baseline and at cycle midpoint; if HDL drops significantly, consider Rosulip (Rosuvastatin) or Atorlip (Atorvastatin); omega-3 supplementation 3–4 g/day and cardiovascular exercise support HDL throughout |
| Blood pressure elevation | Elevated hematocrit increases blood viscosity, which raises systemic vascular resistance and blood pressure; secondary to the erythropoietic effect rather than a direct pressor mechanism; more pronounced at higher doses and longer durations | Monitor blood pressure weekly; manage hematocrit first — it is the root cause; if BP remains elevated after hematocrit is controlled, add Amlip (Amlodipine) 5 mg/day or Sartel (Telmisartan) 40 mg/day |
| Androgenic effects (acne, hair) | Boldenone's androgenic activity is lower than testosterone's but not absent; it converts to dihydroboldenone (DHB) via 5-alpha reductase; users genetically predisposed to androgenic acne or male-pattern hair loss may notice acceleration, particularly at higher doses | For moderate acne: Doxycycline 100 mg/day; for severe or cystic acne: Isotroin (Isotretinoin) 10–20 mg/day; for hair retention: Finasteride DP 1 mg/day + Minoxidil DP topically |
| HPTA suppression / libido on cycle | Boldenone alone causes full HPG axis suppression without providing adequate androgenic support for libido and sexual function — the direct reason a testosterone base is non-negotiable alongside EQ; when testosterone is included at adequate dose, libido suppression mid-cycle is uncommon | Maintain testosterone base throughout the entire cycle at a minimum of 300–400 mg/week; if libido drops despite adequate testosterone, Proviron DP (mesterolone) 50 mg/day raises free testosterone by reducing SHBG binding and supports libido; for ED on cycle: Cialis DP 5 mg/day or 20 mg as needed |
| Gynecomastia (low risk) | Boldenone aromatizes to estradiol at approximately half the rate of testosterone; with moderate testosterone co-administration, total cycle E2 load is lower than a testosterone-only cycle at equivalent mg dose; gyno risk exists but is meaningfully reduced compared to high-aromatization stacks | Low-dose AI such as Arimidex DP (anastrozole) 0.25–0.5 mg EOD is typically sufficient; avoid over-suppressing estradiol — a lean-mass boldenone stack does not require the same AI dose as a high-testosterone protocol; if gyno tissue develops: Nolvadex DP 20 mg/day |
Bloodwork Monitoring
Boldenone's erythropoietic effect makes hematocrit the single most important variable to track on any EQ cycle. The table below covers the full monitoring schedule — from pre-cycle baseline through post-PCT confirmation.
| Lab | When to Test | Target & Action Threshold |
|---|---|---|
| Hematocrit + Hemoglobin | Before cycle; weeks 4, 8, end of cycle | Keep hematocrit below 50%. At 50–52%: reduce dose and retest in 2 weeks. Above 52%: pause cycle; consider therapeutic phlebotomy. Start Aspirin 81 mg/day (Ecosprin) from week 1 as standard prophylaxis against increased blood viscosity |
| Complete Blood Count (CBC) | Before cycle; weeks 6 and 12 | Tracks the full RBC elevation trend; confirms no unexpected changes to white cell or platelet counts alongside the expected erythropoietic response |
| Lipid Panel (Total, HDL, LDL) | Before cycle; week 6–8 | Target LDL below 130 mg/dL; HDL above 35 mg/dL. If HDL drops significantly: add Rosuvastatin (Rosulip) or omega-3 3–4 g/day. Boldenone's lipid impact is moderate — less than an oral 17-aa compound, more than a short testosterone-only cycle |
| Estradiol (E2) | Before cycle; weeks 4–6 | Low-to-moderate aromatization means most users at standard doses do not require an AI — but confirm E2 is in range before assuming it's fine. Optimal on-cycle range: 20–50 pg/mL. Over-suppressing estradiol with an AI on a boldenone cycle is a common mistake |
| Blood Pressure | Weekly (home monitor) | Target systolic below 130 mmHg. Hematocrit management is first-line BP control — elevated RBC mass increases blood viscosity and raises systemic vascular resistance. If BP trends above 140 mmHg despite controlled hematocrit: add Amlodipine (Amlip) 5 mg/day |
| LH + FSH | At PCT start (21 days post last pin) | Confirms depth of HPG axis suppression; used as a baseline to calibrate SERM duration. Full suppression of LH and FSH is expected — recovery of both during PCT confirms the HPG axis is responding |
| Total Testosterone | 4–6 weeks after PCT ends | Target above 400 ng/dL to confirm HPG axis has recovered. If still suppressed, extend PCT or consult an endocrinologist before running another cycle |
Post-Cycle Recovery
Because boldenone undecylenate has a half-life of approximately 14 days, residual blood levels remain suppressive for several weeks after the last injection. PCT begins 21 days after the last pin — not 14. Starting earlier, while boldenone is still clearing, reduces SERM effectiveness and prolongs recovery.
For cycles of 12 weeks or longer, a pre-PCT HCG blast is recommended to restore testicular sensitivity before SERM therapy begins.
| Phase | Products | Protocol |
|---|---|---|
| Pre-PCT Optional — recommended for cycles ≥12 weeks |
HCG 5000 IU Dragon Pharma | 2,500 IU twice per week for 2 weeks, beginning 21 days after last injection; complete HCG before starting SERMs |
| PCT Week 1–2 | Clomid Dragon Pharma + Nolvadex Dragon Pharma |
Clomid 50 mg/day + Nolvadex 40 mg/day |
| PCT Week 3–4 | Clomid Dragon Pharma + Nolvadex Dragon Pharma |
Clomid 25 mg/day + Nolvadex 20 mg/day |
Practical Summary
EQ 300 — Key Takeaways
- Always stack with testosterone — boldenone alone suppresses the HPG axis without replacing androgenic function; a testosterone base is non-negotiable for libido, mood, and hormonal balance throughout the cycle.
- Plan for 12 weeks minimum — the undecylenate ester takes 4–6 weeks to reach stable plasma levels; cycles under 12 weeks do not allow the full appetite stimulation, RBC elevation, and lean mass effects to develop.
- Monitor hematocrit every 4 weeks — erythropoiesis is both the compound's most valuable practical effect and its primary safety variable; keep hematocrit below 50%; start Aspirin 81 mg/day from week 1 as routine prophylaxis.
- PCT at 21 days — not 14 — the undecylenate ester clears more slowly than enanthate; starting SERM therapy before boldenone has cleared reduces LH/FSH recovery rate and extends the suppression window.
- E2 management is conservative here — low-to-moderate aromatization means most users at 300–600 mg/week do not need an AI; confirm estradiol levels with labs before starting one; over-suppression of E2 on a boldenone stack is a common error.
- SHBG and free testosterone — at doses above 400 mg/week alongside moderate testosterone, users who experience libido drop on-cycle benefit from low-dose Proviron (50 mg/day) to reduce SHBG and raise the free testosterone fraction.
EQ 300 remains one of the most consistently used long-ester compounds for athletes prioritizing lean mass quality, appetite support, and sustained vascularity over 12–16 week timelines. Its lower aromatization rate relative to testosterone makes estrogenic management more straightforward, while the erythropoietic effect delivers an endurance advantage that shorter-ester compounds at equivalent doses cannot match. The trade-off is commitment — a minimum 12-week cycle, consistent bloodwork to manage hematocrit, and a PCT window that accounts for slow undecylenate clearance. For users who meet those conditions and prioritize dry, well-retained gains over maximum mass output, EQ 300 built around a testosterone base is a well-established and broadly practical choice.
References
| Source | Topic | Link |
|---|---|---|
| New England Journal of Medicine / PubMed | Supraphysiologic testosterone enanthate in normal men — randomized controlled trial using 600 mg/week testosterone enanthate for 10 weeks, showing increased fat-free mass, muscle size, and strength, especially when combined with resistance training | Bhasin S, et al. (1996) ↗ |
| NCBI Bookshelf / StatPearls | Anabolic steroids overview — synthetic testosterone-derived AAS pharmacology, androgen receptor mechanism, anabolic-androgenic effects, injectable ester context, misuse patterns, monitoring, and adverse effect profile | StatPearls: Anabolic Steroids ↗ |
| NCBI Bookshelf / Endotext | Androgen physiology and pharmacology — testosterone and androgen derivative mechanisms of action, androgen receptor activity, HPG axis suppression, estradiol aromatization, androgen ester pharmacokinetics, and androgen misuse context | Endotext: Androgen Physiology, Pharmacology, Use and Misuse ↗ |
| Sports Medicine / PubMed | Effects of androgenic-anabolic steroids in athletes — comprehensive review of AAS pharmacokinetics, anabolic effects on muscle protein synthesis, erythropoietic stimulation and hematocrit elevation, cardiovascular risk, and lipid profile changes across multiple AAS compound classes | Hartgens F, Kuipers H (2004) ↗ |
| Journal of Clinical Endocrinology & Metabolism / PubMed | Androgen abuse in athletes: detection and consequences — review covering erythrocytosis and blood viscosity risk from supraphysiologic androgen use, HPG axis suppression patterns, lipid profile impact, and cardiovascular consequences specific to prolonged AAS cycles | Basaria S (2010) ↗ |
What is EQ 300?
EQ 300 is an injectable Boldenone Undecylenate for lean muscle growth; see What is Boldenone Undecylenate. It enhances performance—consult professionals for safe use.
What is EQ 300 used for?
EQ 300 is used for lean muscle growth and endurance in bodybuilding; see Key Benefits. It suits bulking or cutting—consult professionals for safe use.
How long does EQ 300 stay in your system?
With a 14-day half-life, it's detectable for 4-6 months; see Mechanism of Action. Plan PCT accordingly—consult professionals.
Is EQ 300 dangerous?
It's safe with proper use and monitoring; see Side Effects. Risks are manageable with ancillaries—consult professionals for safety.
How to use EQ 300?
Inject 300-600 mg/week, split weekly; see How to Use. Use with diet and monitoring—consult for tailored plans.
How does EQ 300 work?
EQ 300 works by increasing protein synthesis and nitrogen retention, helping create an anabolic environment that supports muscle development and recovery.
How long does it take to notice the effects of EQ 300?
As a long-ester compound, EQ 300 typically produces gradual results. Many users report improvements in endurance, recovery, muscle fullness, and strength after several weeks of use.
What are the main benefits of EQ 300?
Commonly reported benefits include lean muscle gains, improved strength, enhanced recovery, increased training capacity, and a more athletic physique without excessive water retention.
Related Products
